One of the biggest pharmaceutical firms in India and a pioneer in specialized generics is Sun Pharmaceutical Industries Ltd. The business is well-established in the US, India, and a number of emerging regions. Sun Pharma has managed to hold onto its position as a leading player in the global pharmaceutical sector by maintaining a strong product portfolio and a focus on research and development.
This article will examine Sun Pharma’s stock more closely and provide a thorough analysis of the company’s growth potential in the upcoming years. We’ll look at the major variables that could have an impact on the company’s success and give a detailed forecast of its share price from 2024 to 2030.
CLICK HERE TO KNOW: TATA POWER COMPANY SHARE PRICE TARGET 2024 TO 2030: CAN TATA POWER REACH 2000 INR?
SUN PHARMA SHARE PRICE TARGET 2024
| Month | Maximum Price | Minimum Price |
|---|---|---|
| March 2024 | ₹1,552.10 | ₹1,349.65 |
| April 2024 | ₹1,506.89 | ₹1,310.34 |
| May 2024 | ₹1,484.62 | ₹1,290.98 |
| June 2024 | ₹1,538.07 | ₹1,337.45 |
| July 2024 | ₹1,522.69 | ₹1,324.08 |
| August 2024 | ₹1,583.60 | ₹1,377.04 |
| September 2024 | ₹1,646.94 | ₹1,432.12 |
| October 2024 | ₹1,614.65 | ₹1,404.04 |
| November 2024 | ₹1,679.23 | ₹1,460.20 |
| December 2024 | ₹1,696.03 | ₹1,474.81 |
In March 2024, Sun Pharma is set to reach a maximum price of ₹1,552.10, showcasing promising growth in the market. As the year progresses, by December 2024, the company is expected to soar to a maximum price of ₹1,696.03, indicating a robust upward trajectory. Throughout the year, Sun Pharma is poised to maintain its competitive edge and solidify its position as a key player in the pharmaceutical industry.
CLICK HERE: INDUSIND BANK SHARE PRICE TARGET 2024 TO 2030: CAN INDUSIND BANK REACH 5000 INR?
SUN PHARMA SHARE PRICE TARGET 2025
| Month | Maximum Price | Minimum Price |
|---|---|---|
| January 2025 | ₹1,697.72 | ₹1,305.94 |
| February 2025 | ₹1,701.12 | ₹1,308.56 |
| March 2025 | ₹1,736.85 | ₹1,336.04 |
| April 2025 | ₹1,702.79 | ₹1,309.84 |
| May 2025 | ₹1,653.20 | ₹1,271.69 |
| June 2025 | ₹1,727.59 | ₹1,328.92 |
| July 2025 | ₹1,693.72 | ₹1,302.86 |
| August 2025 | ₹1,746.10 | ₹1,343.15 |
| September 2025 | ₹1,767.05 | ₹1,359.27 |
| October 2025 | ₹1,813.00 | ₹1,394.61 |
| November 2025 | ₹1,858.32 | ₹1,429.48 |
| December 2025 | ₹1,941.94 | ₹1,493.80 |
Throughout 2025, Sun Pharma is expected to experience fluctuating market conditions, with its maximum and minimum prices varying across the months. The year is predicted to commence on a positive note, with Sun Pharma’s maximum price forecasted to reach ₹1,697.72 in January, indicating a promising start. As the months progress, the company’s prices are anticipated to exhibit a generally upward trend, culminating in December with a projected maximum price of ₹1,941.94, underscoring substantial growth potential. Conversely, the minimum price is expected to fluctuate between ₹1,271.69 in May and ₹1,493.80 in December, reflecting the resilience of Sun Pharma amidst market uncertainties. Despite these fluctuations, Sun Pharma is poised to maintain its competitive position and continue its trajectory of growth and innovation in the pharmaceutical industry throughout 2025.
SUN PHARMA SHARE PRICE TARGET 2026 TO 2030
| SUN PHARMA SHARE PRICE TARGET BY | Maximum Price | Minimum Price |
| 2026 | ₹2,372.71 | ₹1,527.03 |
| 2027 | ₹2,892.67 | ₹1,861.67 |
| 2028 | ₹3,526.57 | ₹2,269.63 |
| 2029 | ₹4,299.38 | ₹2,767.00 |
| 2030 | ₹5,241.54 | ₹3,373.36 |
In the upcoming years, Sun Pharma is anticipated to embark on a remarkable journey of growth in its share prices, with each successive year painting a picture of ascending value. As we look forward to 2026, Sun Pharma’s maximum share price is expected to climb to ₹2,372.71, marking a significant stride in market valuation. Simultaneously, the minimum price is projected to stabilize at ₹1,527.03, laying the groundwork for potential fluctuations. Stepping into 2027, Sun Pharma’s trajectory is poised to maintain its upward momentum, with the maximum price forecasted to surge to ₹2,892.67, indicative of the company’s sustained growth trajectory and investor confidence. Similarly, the minimum price is anticipated to experience an uptick, settling at ₹1,861.67, underscoring Sun Pharma’s resilience amidst evolving market dynamics. As we progress through the years, this pattern of growth is expected to persist, with Sun Pharma’s maximum price poised to reach ₹3,526.57 in 2028, ₹4,299.38 in 2029, and ₹5,241.54 in 2030. Correspondingly, the accompanying minimum prices are anticipated to witness incremental increases, reflecting the company’s unwavering commitment to innovation and market leadership in the pharmaceutical landscape. These forthcoming projections illuminate Sun Pharma’s promising trajectory and underscore its potential to create enduring value for stakeholders in the years ahead.
CLICK HERE: AU SMALL FINANCE BANK SHARE PRICE TARGET 2024 TO 2030: CAN ASF BANK REACH 3000 INR?
FINANCIAL STRENGTH OF SUN PHARMA (2019 TO 2023)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
| Sales + | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 |
| Expenses + | 22,689 | 25,855 | 25,028 | 28,397 | 32,109 |
| Operating Profit | 6,377 | 6,983 | 8,470 | 10,258 | 11,777 |
| OPM % | 22% | 21% | 25% | 27% | 27% |
| Other Income + | -258 | 382 | -3,449 | -3,505 | 333 |
| Interest | 555 | 303 | 141 | 127 | 172 |
| Depreciation | 1,753 | 2,053 | 2,080 | 2,144 | 2,529 |
| Profit before tax | 3,810 | 5,010 | 2,799 | 4,481 | 9,408 |
| Tax % | 16% | 16% | 18% | 24% | 9% |
| Net Profit + | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 |
| EPS in Rs | 11.11 | 15.69 | 12.1 | 13.64 | 35.32 |
| Dividend Payout % | 25% | 25% | 62% | 73% | 33% |
Over the five-year period from March 2019 to March 2023, the financial statements of the company depict a consistent growth trajectory. In March 2019, total sales amounted to 29,066, outpacing expenses at 22,689, resulting in an operating profit of 6,377. The operating profit margin (OPM %) stood at 22%, reflecting a solid operational performance. Despite a negative figure in other income at -258, the company reported a net profit of 3,208, with earnings per share (EPS) at 11.11.
March 2020 showcased further growth, with sales reaching 32,838 and operating profit at 6,983, translating to an OPM % of 21%. The net profit surged to 4,172, and EPS increased to 15.69. In March 2021, sales continued to rise to 33,498, accompanied by operating profit of 8,470 and an OPM % of 25%. Despite a negative other income of -3,449, the net profit reached 2,272, and EPS was reported at 12.1.
March 2022 marked another positive year, with sales escalating to 38,654, operating profit reaching 10,258, and OPM % increasing to 27%. The net profit showed a significant rise to 3,389, with an EPS of 13.64. In the latest financial year, March 2023, the company experienced substantial growth, reporting sales of 43,886 and an operating profit of 11,777, maintaining an OPM % of 27%. The net profit soared to 8,513, and EPS reached 35.32.
Dividend payout percentages varied, with a notable increase in March 2021 at 62%, followed by a peak in March 2022 at 73%, indicating a commitment to shareholder returns. These financial statements underscore the company’s consistent profitability, operational efficiency, and strategic financial management over the five-year period.
CLICK HERE FOR MORE: IDFC FIRST BANK LTD SHARE PRICE TARGET: CAN IDFC BANK REACH 200 INR?
FAQ’s
What is Sun Pharmaceutical Industries Ltd Share Price Prediction for 2025?
Sun Pharmaceutical Industries Ltd Could reach ₹1,941.94 by the end of 2025.
What is the Price Prediction of Sun Pharmaceutical Industries Ltd for 2030?
Sun Pharmaceutical Industries Ltd could reach ₹5,241.54 as its maximum price.
What is Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd is an Indian multinational pharmaceutical company headquartered in Mumbai, India. It specializes in the development and manufacturing of generic and branded drugs.
How has Sun Pharma’s revenue growth been over the years?
Sun Pharma’s revenue has demonstrated a consistent upward trend over the years from March 2019 to March 2023. In March 2019, the company reported sales of ₹29,066, and this figure has steadily increased in subsequent years. By March 2020, sales rose to ₹32,838, followed by further growth to ₹33,498 in March 2021. The positive trajectory continued with sales reaching ₹38,654 in March 2022 and further escalating to ₹43,886 in March 2023.
How has Sun Pharma’s PAT growth been over the years?
Sun Pharma’s Profit After Tax (PAT) has demonstrated consistent growth over the years, rising from ₹3,208 in March 2019 to the highest recorded figure of ₹8,513 in March 2023. This upward trend highlights the company’s effective financial performance and sustained profitability.
CONCLUSION: SUN PHARMACEUTICAL INDUSTRIES LTD SHARE PRICE TARGET
According to Sun Pharmaceutical Industries Ltd’s financial statements for the past five years, the company has consistently increased its total sales, profit after tax (PAT), and overall profitability. The business has also had success controlling costs and keeping a strong profit margin. It is crucial to remember that sales growth and PAT increase have fluctuated in previous years.
The choice to invest in Sun Pharmaceutical Industries Ltd should be made after carefully evaluating the company’s financial and operational performance and taking into account any additional external factors that might have an impact on the pharmaceutical business. A financial counsellor should always be consulted before making any significant financial decision.
Leave a Reply